Recovery
BPC-157 Arginate
Also called PDA, Pentadeca Arginate
per administration
The amounts going around come from sellers and forums, not from any study.
Quick start
BPC-157 Arginate at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 200–500 mcg per administration
- How often
- Every day
- Where
- Commonly subcutaneous Sites and rotation
- Time to steady level
- ~20 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for BPC-157 Arginate describe 200–500 mcg per administration. Descriptive only, not a recommendation.
No pharmacokinetic data of its own; carried over from BPC-157, which is poorly characterized.
An arginate salt form of BPC-157, marketed as pentadeca arginate. No study covers the salt separately from BPC-157, whose own evidence is preclinical and community-derived, so its figures are carried over here and no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.02× single dose
- Time to steady state
- 20hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- BPC-157 preclinical literatureNo literature covers the arginate salt on its own; see the BPC-157 page for the parent's preclinical sources.